SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection

NCT07096882 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: SDT-M001 injection

Sponsor

Cytocraft Biopharmaceutical Co., Ltd.